• LAST PRICE
    2.8500
  • TODAY'S CHANGE (%)
    Trending Down-0.2500 (-8.0645%)
  • Bid / Lots
    2.8000/ 1
  • Ask / Lots
    3.1800/ 3
  • Open / Previous Close
    3.1900 / 3.1000
  • Day Range
    Low 2.7900
    High 3.1900
  • 52 Week Range
    Low 1.4500
    High 4.8599
  • Volume
    28,111
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.1
TimeVolumeCASI
09:32 ET8803.19
09:36 ET1003.15
09:39 ET1003.12
09:41 ET6803.12
09:57 ET12573.15
10:39 ET1933.1499
10:42 ET19003.15
10:46 ET1003.15
11:02 ET13373.1
11:06 ET5003.05
11:58 ET11493
12:07 ET1003.05
12:54 ET1853
01:12 ET1003.005
01:17 ET10002.9701
01:19 ET11002.97
01:39 ET3622.97
02:04 ET6622.91
02:13 ET56432.91
02:22 ET1002.9
02:44 ET5002.9599
03:03 ET1002.98
03:23 ET26252.91
03:27 ET22812.91
03:30 ET13142.93
03:32 ET1002.92
03:54 ET2002.88
03:56 ET1752.87
03:57 ET1002.79
03:59 ET3002.85
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCASI
CASI Pharmaceuticals Inc
38.0M
-1.0x
---
United StatesMEIP
MEI Pharma Inc
50.0M
-1.3x
---
United StatesJAN
Janone Inc
4.1M
-0.9x
---
United StatesMDXH
MDxHealth SA
63.1M
-1.5x
---
United StatesHARP
Harpoon Therapeutics Inc
30.1M
-0.5x
---
United StatesCSBR
Champions Oncology Inc
71.0M
-22.7x
---
As of 2023-06-03

Company Information

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products. The Company's product EVOMELA is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. The Company’s pipeline includes CNCT19, BI-1206, CB-5339, CID-103, Octreotide, and Thiotepa. CNCT19 is used for the treatment of patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). CB-5339 is a Valosin-containing protein (VCP/p97) inhibitor focused on VCP/p97 as a target in protein homeostasis, deoxyribonucleic acid (DNA) damage response, and other cellular stress pathways for use in the treatment of patients with various malignancies. Thiotepa is a chemotherapeutic agent used prior to certain allogeneic hemopoietic stem cell transplants.

Contact Information

Headquarters
9620 Medical Center Dr Ste 300ROCKVILLE, MD, United States 20850-3396
Phone
240-864-2600
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
Wei-wu He
President, Principal Financial Officer
Wei Zhang
Chief Operating Officer
Chunhua Wang
Executive Vice President, Chief Medical Officer
Alexander Zukiwski
Vice President, Controller
Kun Qian

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$38.0M
Revenue (TTM)
$42.4M
Shares Outstanding
13.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.45
EPS
$-2.84
Book Value
$3.31
P/E Ratio
-1.0x
Price/Sales (TTM)
0.9
Price/Cash Flow (TTM)
---
Operating Margin
-80.10%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.